Global Immunotherapy Drugs Market 2016-2020

March 29, 2016
This market research report presents a comprehensive segmentation of the global immunotherapy drugs market by type of immunotherapy (mAbs, vaccines, immune checkpoint inhibitors, non-specific immunotherapies, and others), by therapy area (oncology, infectious disease, autoimmune and inflammatory disorders, respiratory diseases, and others), and by geography (the Americas, APAC, and EMEA). Key vendors are AbbVie, Amgen, Bristol-Myers Squibb, F.Hoffmann-La Roche, Johnson & Johnson, and Merck.

Overview of the global immunotherapy drugs market

Technavio’s market research analyst predicts that the global immunotherapy drugs market will grow at a steady CAGR of close to 12% by 2020. During a rise in cancer and a number of autoimmune diseases, the need for immunotherapy drugs is on the rise. Furthermore, with the increasing demand for mAbs, the market for immunotherapy drugs will have a positive outlook until the end of the forecast period. mAbs have a high affinity for specific disease cells and areas that need treatment. Consequently, they can be used for therapies like radioimmunotherapy and antibody-directed enzyme prodrug therapy. The augmented usage of these antibodies in drug development will help to bolster the market’s revenue generating capacity over the course of the next four years.

An important factor impelling the prospects for growth in this market is the emergence of biosimilars. Unlike generic drugs, which have active pharmaceutical ingredients similar to original drugs, biosimilars are almost identical to their originator biologic compounds. Since biosimilars help to make treatments more accessible to patients and are less expensive than biologics, their sale among the end users is anticipated to increase significantly over the next few years.

Segmentation by type of immunotherapy and analysis of the immunotherapy drugs market

  • mAbs
  • Vaccines
  • Immune checkpoint inhibitors
  • Non-specific immunotherapies

During 2015, the mAbs segment dominated this market and accounted for an impressive market share of nearly 61%. The development of new drugs and the entry of new molecules like zanolimumab, elotuzumab, obinutuzumab, and onartuzumab into the market will aid in the growth of this market segment during the forecast period. 

Geographical segmentation and analysis of the immunotherapy drugs market

  • Americas
  • APAC
  • EMEA

The Americas dominated the global market with over 50% market share in 2015. The market is flourishing in this region due to the higher incidences of cancer, infectious diseases, and autoimmune diseases in the US. Additionally, factors such as the high affordability of therapies due to the presence of well-structured reimbursement plans will also spur the prospects for market growth until 2020.

Competitive landscape and key vendors

The global market for immunotherapy drugs is highly competitive due to the presence of a number of large and small vendors. Many of these vendors have a huge global presence and enter into strategic alliances to aid in the manufacture and marketing of essential drugs. Safety and effectiveness of drugs are key factors, which will give vendors an edge in the marketplace.

Key vendors in this market are -

  • AbbVie
  • Amgen
  • Bristol-Myers Squibb
  • F.Hoffmann-La Roche
  • Johnson & Johnson
  • Merck

Other prominent vendors are AB Science. Ablynx, Acorda Therapeutics, ADC Therapeutics, Aduro Biotech, Advantagene, Advaxis, Agensys, Agenus, Alder Biopharmaceuticals, AlphaVax, Altor BioScience, Antares Pharma, Antigen Express, Argos Therapeutics, Astellas Pharma, AstraZeneca, AVAX Technologies, Bavarian Nordic, Baxter, Bayer, Biogen, Biotech Pharmaceutical, Biothera, Boehringer Ingelheim, Can-Fite BioPharma, Celgene, Celldex Therapeutics, Celltrion, Cel-Sci, ChemoCentryx, Chugai Pharmaceutical, Coherus BioSciences, CTI BioPharma, CureVac, Daiichi Sankyo, Eisai, Eli Lilly, Fortress Biotech, Galena Biopharma, Genexine, Genmab, Gilead Sciences, GSK, GlobeImmune, Gradalis, Heat Biologics, Hospira, Idera, Inmatics, ImmunoCellular Therapeutics, Immunomedics, ImmuPharma, Immutep, Incyte, Inovio Pharmaceuticals, Intas Pharmaceuticals, Invion, ISA Pharmaceuticals, Janssen Biotech, Juvaris Biotherapeutics, KaloBios Pharmaceuticals, Kyowa Hakko Kirin, Lexicon Pharmaceuticals, MedImmune, Morphotek, Neovii Biotech, Northwest Biotherapeutics, Novartis, NovaRx, Novo Nordisk, OncoMed Pharmaceuticals, Oncothyreon, Oncovir, Opexa Therapeutics, Oxford BioMedica, Pfizer, Prima BioMed, Principia, Progenics, Provectus Biopharmaceuticals, Regeneron, Sandoz, Sanofi, Santarus, Seattle Genetics, Sotio, Spectrum Pharmaceuticals, Takeda, TG Therapeutics, Transgene, UbiVac, UCB, Vaccinex, Vaccinogen, Vaxon Biotech, Vertex Pharmaceuticals, Vical, Vitae Pharmaceuticals, and XBiotech.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2020?
  • What are the key factors driving the global immunotherapy drugs market?
  • What are the key market trends impacting the growth of the global immunotherapy drugs market?
  • What are the challenges to market growth for immunotherapy drugs?
  • Who are the key vendors in the global immunotherapy drugs market?
  • What are the market opportunities and threats faced by the vendors in the immunotherapy drugs market?
  • Trending factors influencing the market shares of the Americas, APAC, and EMEA.
  • What are the key outcomes of the five forces analysis of the global immunotherapy drugs market?

Technavio also offers customization on reports based on specific client requirement.

Related reports

Immunotherapy is a mode of treatment that uses certain parts of a person's immune system to fight diseases like cancer. With the properties of the immune system, immunotherapies have better chances of successfully fighting cancer and protect patients from the disease for a longer period. An increase in regulatory support by various governments to develop cancer immunotherapies will aid in the growth of this market during the next four years.

The global immunotherapy drugs market is part of Technavio’s healthcare and life sciences research portfolio. This portfolio provides a comprehensive market analysis along with the market share, market sizing, and market segmentations covering areas such as cardiovascular and metabolic disorders, central nervous system, oncology, medical imaging, life science research tools, and vaccines. These market research reports provide a perspective on the various market opportunities and market threats along with the key trends that would influence the market growth during the forecast period. It presents insights into the changing competitive landscape and a detailed profiling and market analysis of the vendors. Also covered in the research are the key regions or countries that would have an impact on the market during the assessment years.